Johnson & Johnson (NYSE:JNJ) Shares Acquired by Consilium Wealth Advisory LLC

Posted by Defense World Staff on Sep 24th, 2023

Consilium Wealth Advisory LLC grew its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 1.4% during the 2nd quarter, Holdings Channel reports. The firm owned 7,851 shares of the company’s stock after purchasing an additional 111 shares during the quarter. Johnson & Johnson makes up approximately 0.9% of Consilium Wealth Advisory LLC’s investment portfolio, making the stock its 24th largest position. Consilium Wealth Advisory LLC’s holdings in Johnson & Johnson were worth $1,300,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also modified their holdings of the company. MTM Investment Management LLC increased its stake in Johnson & Johnson by 0.5% during the 1st quarter. MTM Investment Management LLC now owns 11,283 shares of the company’s stock worth $1,749,000 after buying an additional 61 shares during the period. OneAscent Financial Services LLC increased its stake in Johnson & Johnson by 3.3% during the 1st quarter. OneAscent Financial Services LLC now owns 1,986 shares of the company’s stock worth $308,000 after buying an additional 63 shares during the period. Beech Hill Advisors Inc. increased its stake in Johnson & Johnson by 0.3% during the 2nd quarter. Beech Hill Advisors Inc. now owns 23,595 shares of the company’s stock worth $3,906,000 after buying an additional 63 shares during the period. FIDELIS iM LLC increased its stake in Johnson & Johnson by 3.1% during the 4th quarter. FIDELIS iM LLC now owns 2,117 shares of the company’s stock worth $374,000 after buying an additional 64 shares during the period. Finally, Well Done LLC increased its stake in Johnson & Johnson by 0.4% during the 1st quarter. Well Done LLC now owns 15,584 shares of the company’s stock worth $2,415,000 after buying an additional 64 shares during the period. Institutional investors and hedge funds own 68.40% of the company’s stock.

Insider Buying and Selling

In related news, insider William Hait sold 14,698 shares of the firm’s stock in a transaction dated Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total transaction of $2,528,056.00. Following the transaction, the insider now owns 87,747 shares of the company’s stock, valued at $15,092,484. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In related news, insider William Hait sold 14,698 shares of the firm’s stock in a transaction dated Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total transaction of $2,528,056.00. Following the transaction, the insider now owns 87,747 shares of the company’s stock, valued at $15,092,484. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, VP Peter Fasolo sold 20,000 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, July 25th. The shares were sold at an average price of $170.32, for a total value of $3,406,400.00. Following the completion of the sale, the vice president now directly owns 102,696 shares in the company, valued at approximately $17,491,182.72. The disclosure for this sale can be found here. Corporate insiders own 0.20% of the company’s stock.

Wall Street Analysts Forecast Growth

JNJ has been the topic of several recent research reports. StockNews.com downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research note on Wednesday. Morgan Stanley dropped their price objective on shares of Johnson & Johnson from $187.00 to $172.00 and set an “equal weight” rating on the stock in a research report on Thursday, August 31st. Stifel Nicolaus increased their price objective on shares of Johnson & Johnson from $165.00 to $175.00 in a research report on Friday, July 21st. HSBC assumed coverage on shares of Johnson & Johnson in a research report on Wednesday, September 6th. They issued a “hold” rating and a $175.00 price objective on the stock. Finally, Raymond James dropped their price objective on shares of Johnson & Johnson from $184.00 to $179.00 and set an “outperform” rating on the stock in a research report on Tuesday, September 5th. Nine analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat, Johnson & Johnson has a consensus rating of “Hold” and a consensus target price of $170.65.

Read Our Latest Analysis on Johnson & Johnson

Johnson & Johnson Stock Down 0.7 %

Shares of NYSE:JNJ opened at $160.50 on Friday. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.12 and a quick ratio of 0.88. The stock has a market cap of $417.13 billion, a P/E ratio of 32.49, a P/E/G ratio of 3.27 and a beta of 0.54. Johnson & Johnson has a 1-year low of $150.11 and a 1-year high of $181.04. The firm has a fifty day moving average price of $166.51 and a 200 day moving average price of $162.00.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its earnings results on Thursday, July 20th. The company reported $2.80 earnings per share for the quarter, topping the consensus estimate of $2.62 by $0.18. Johnson & Johnson had a net margin of 13.35% and a return on equity of 36.72%. The business had revenue of $25.53 billion during the quarter, compared to the consensus estimate of $24.63 billion. During the same quarter in the prior year, the firm earned $2.59 earnings per share. The business’s quarterly revenue was up 6.3% compared to the same quarter last year. Sell-side analysts predict that Johnson & Johnson will post 10.02 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, September 7th. Investors of record on Monday, August 28th were issued a dividend of $1.19 per share. This represents a $4.76 dividend on an annualized basis and a dividend yield of 2.97%. The ex-dividend date was Friday, August 25th. Johnson & Johnson’s dividend payout ratio is currently 96.36%.

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.